Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity.

Zambrano-Galván G, Reyes-Romero M, Bologna-Molina R, Almeda-Ojeda OE, Lemus-Rojero O.

Case Rep Dent. 2014;2014:792615. doi: 10.1155/2014/792615. Epub 2014 Jul 10.

2.

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB.

Oncotarget. 2014 Feb 28;5(4):1052-61.

3.

The Diverging Routes of BORIS and CTCF: An Interactomic and Phylogenomic Analysis.

Jabbari K, Heger P, Sharma R, Wiehe T.

Life (Basel). 2018 Jan 30;8(1). pii: E4. doi: 10.3390/life8010004.

4.

The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.

Hore TA, Deakin JE, Marshall Graves JA.

PLoS Genet. 2008 Aug 29;4(8):e1000169. doi: 10.1371/journal.pgen.1000169.

5.

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.

Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV.

Semin Cancer Biol. 2002 Oct;12(5):399-414. Review.

PMID:
12191639
6.

Discovering a binary CTCF code with a little help from BORIS.

Lobanenkov VV, Zentner GE.

Nucleus. 2018 Jan 1;9(1):33-41. doi: 10.1080/19491034.2017.1394536. Epub 2017 Dec 5.

PMID:
29077515
7.

The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.

Pugacheva EM, Teplyakov E, Wu Q, Li J, Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, Hutchins AP, Lobanenkov V, Strunnikov A.

Epigenetics Chromatin. 2016 Aug 31;9(1):35. doi: 10.1186/s13072-016-0084-2. eCollection 2016.

8.

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.

9.

CTCF and BORIS in genome regulation and cancer.

Marshall AD, Bailey CG, Rasko JE.

Curr Opin Genet Dev. 2014 Feb;24:8-15. doi: 10.1016/j.gde.2013.10.011. Epub 2013 Dec 14. Review.

PMID:
24657531
10.

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.

11.

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.

Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6806-11.

12.

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.

Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V.

Nucleic Acids Res. 2007;35(21):7372-88. Epub 2007 Oct 25.

13.

Expression of the epigenetic factor BORIS (CTCFL) in the human genome.

de Necochea-Campion R, Ghochikyan A, Josephs SF, Zacharias S, Woods E, Karimi-Busheri F, Alexandrescu DT, Chen CS, Agadjanyan MG, Carrier E.

J Transl Med. 2011 Dec 14;9:213. doi: 10.1186/1479-5876-9-213. Review.

14.

BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Link PA, Zhang W, Odunsi K, Karpf AR.

Cancer Immun. 2013;13:6. Epub 2013 Jan 22.

15.

Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.

Pugacheva EM, Rivero-Hinojosa S, Espinoza CA, Méndez-Catalá CF, Kang S, Suzuki T, Kosaka-Suzuki N, Robinson S, Nagarajan V, Ye Z, Boukaba A, Rasko JE, Strunnikov AV, Loukinov D, Ren B, Lobanenkov VV.

Genome Biol. 2015 Aug 14;16:161. doi: 10.1186/s13059-015-0736-8.

16.

Widespread expression of BORIS/CTCFL in normal and cancer cells.

Jones TA, Ogunkolade BW, Szary J, Aarum J, Mumin MA, Patel S, Pieri CA, Sheer D.

PLoS One. 2011;6(7):e22399. doi: 10.1371/journal.pone.0022399. Epub 2011 Jul 19.

17.

BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.

Velázquez-Hernández N, Reyes-Romero MA, Barragán-Hernández M, Guerrero-Romero F, Rodríguez-Moran M, Aguilar-Durán M, Lazalde Medina B.

Genet Mol Res. 2015 Jun 10;14(2):6094-100. doi: 10.4238/2015.June.8.7.

18.

Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.

Rivero-Hinojosa S, Kang S, Lobanenkov VV, Zentner GE.

Sci Rep. 2017 Feb 1;7:41279. doi: 10.1038/srep41279. Erratum in: Sci Rep. 2017 Aug 04;7:46891.

19.

BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.

Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P.

PLoS One. 2010 Mar 17;5(3):e9738. doi: 10.1371/journal.pone.0009738.

20.

DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.

Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR.

Cancer Immun. 2007 Dec 21;7:21.

Supplemental Content

Support Center